The worldwide diversity of HIV-1 presents an unprecedented challenge for vaccine development1, 2. Antigens derived from natural HIV-1 sequences have elicited only a limited breadth of cellular immune responses in nonhuman primate studies and clinical trials to date. Polyvalent 'mosaic' antigens, in contrast, are designed to optimize cellular immunologic coverage of global HIV-1 sequence diversity3. Here we show that mosaic HIV-1 Gag, Pol and Env antigens expressed by recombinant, replication-incompetent adenovirus serotype 26 vectors markedly augmented both the breadth and depth without compromising the magnitude of antigen-specific T lymphocyte responses as compared with consensus or natural sequence HIV-1 antigens in rhesus monkeys. Polyvalent mosaic antigens therefore represent a promising strategy to expand cellular immunologic vaccine coverage for genetically diverse pathogens such as HIV-1.
At a glance
- Challenges in the development of an HIV-1 vaccine. Nature 455, 613–619 (2008).
- T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J. Virol. 83, 8300–8314 (2009). , &
- Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13, 100–106 (2007). et al.
- CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13, 46–53 (2007). et al.
- Immune control of an SIV challenge by a T-cell–based vaccine in rhesus monkeys. Nature 457, 87–91 (2009). et al.
- Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81, 4654–4663 (2007). et al.
- A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc. Natl. Acad. Sci. USA 105, 10489–10494 (2008). et al.
- Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 24, 6893–6904 (2006). et al.
- Mixed-Effects Models in S and S-plus (Springer, New York, 2000). &
- Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239–243 (2006). et al.
- Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. 64, 12.1.1–12.1.17 (2004).
- Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J. Virol. 83, 2201–2215 (2009). et al.
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881–1893 (2008). et al.
- HIV-1 vaccine–induced immunity in the test-of-concept STEP Study: a case-cohort analysis. Lancet 372, 1894–1905 (2008). et al.
- The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206, 1253–1272 (2009). et al.
- Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants. Nat. Immunol. 6, 247–252 (2005). et al.
- Depletion of CD8+ cells in sooty mangabey monkeys naturally infected with simian immunodeficiency virus reveals limited role for immune control of virus replication in a natural host species. J. Immunol. 178, 8002–8012 (2007). et al.
- Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat. Med. 15, 861–865 (2009). et al.
- Web-based design and evaluation of T-cell vaccine candidates. Bioinformatics 24, 1639–1640 (2008). et al.
- Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46, 1769–1781 (2008). et al.
- Supplementary Text and Figures (1M)
Supplementary Figures 1–4